Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab + Short-course RT in MGMT-unmethylated GBM
NCT03367715Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Feb 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in glioblastoma (GBM), sponsored by NYU Langone Health. Started Feb 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03367715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367715.